By Lina carolina 
An innovative MRI-based imaging technique developed at the University of Cambridge holds the potential to dramatically alter the landscape of ovarian cancer treatment, offering oncologists the unprecedented ability to predict patient response to therapy and rapidly assess treatment efficacy in patient-derived cell models. This breakthrough, detailed in the journal Oncogene, utilizes hyperpolarized carbon-13 imaging, a method capable of amplifying MRI signals by an astounding factor of over 10,000.
Unveiling Tumour Subtypes and Treatment Sensitivity
The core of this advancement lies in the technique’s capacity to differentiate between distinct subtypes of ovarian cancer, thereby revealing their inherent sensitivities to therapeutic interventions. Researchers meticulously applied this method to patient-derived cell models that accurately replicate the complex behavior of high-grade serous ovarian cancer (HGSOC), the most prevalent and lethal form of the disease. The hyperpolarized carbon-13 imaging technique demonstrably distinguished between tumours that were sensitive to Carboplatin, a cornerstone of first-line chemotherapy for ovarian cancer, and those that exhibited resistance.
This crucial distinction translates into a profound clinical implication: oncologists can now anticipate a patient’s likely response to treatment with greater accuracy and, critically, monitor the treatment’s effectiveness within a remarkably short timeframe of 48 hours. The current paradigm often necessitates weeks, if not months, of waiting for patients to ascertain whether their cancer is responding to therapy. The rapid feedback loop offered by this new technique promises to empower clinicians to swiftly adjust and personalize treatment regimens, tailoring them to individual patient needs within mere days.
A Leap Forward from Current Diagnostic Methods
The study’s findings highlight a significant advantage over established diagnostic tools. Researchers conducted a comparative analysis between the hyperpolarized imaging technique and Positron Emission Tomography (PET) scans, a modality already integrated into routine clinical practice. The results indicated that PET scans failed to detect the subtle metabolic differences that characterize distinct tumour subtypes, rendering them incapable of predicting the specific type of tumour present. This limitation underscores the unique diagnostic power of the hyperpolarized carbon-13 approach.
Professor Kevin Brindle, a senior author of the report and a researcher at the University of Cambridge’s Department of Biochemistry, emphasized the broader implications of this technology. "This technique tells us how aggressive an ovarian cancer tumour is," Professor Brindle stated. "It could allow doctors to assess multiple tumours in a patient to give a more holistic assessment of disease prognosis so the most appropriate treatment can be selected."
Ovarian cancer frequently presents with multiple tumours disseminated throughout the abdominal cavity. Obtaining biopsies from all these tumours is often impractical, and critically, these tumours can exhibit diverse subtypes with varying responses to treatment. The non-invasive nature of MRI, coupled with the enhanced sensitivity of hyperpolarized imaging, offers a revolutionary solution, enabling oncologists to simultaneously evaluate all tumours present.
Professor Brindle further elaborated on the diagnostic and monitoring capabilities. "We can image a tumour pre-treatment to predict how likely it is to respond, and then we can image again immediately after treatment to confirm whether it has indeed responded," he explained. "This will help doctors to select the most appropriate treatment for each patient and adjust this as necessary." He also touched upon the psychological impact of the diagnosis: "One of the questions cancer patients ask most often is whether their treatment is working. If oncologists can speed their patients onto the best treatment, then it’s clearly of benefit."
The path forward for this groundbreaking technique involves its translation into clinical trials with ovarian cancer patients, a development scientists anticipate within the next few years.
The Science Behind the Breakthrough: Hyperpolarized Carbon-13 Imaging
The hyperpolarized carbon-13 imaging technique operates on a sophisticated principle involving an injectable solution containing a specially "labelled" form of pyruvate, a naturally occurring molecule. Once administered, this pyruvate permeates the body’s cells. The MRI scanner then visualizes the rate at which pyruvate is metabolized – broken down – into lactate. This metabolic rate serves as a critical indicator, revealing the specific tumour subtype and, consequently, its susceptibility or resistance to therapeutic agents.
This study significantly bolsters the growing body of evidence supporting the broader clinical utility of hyperpolarized carbon-13 imaging. Professor Brindle, who also holds a position at the Cancer Research UK Cambridge Institute, has dedicated the past two decades to advancing this imaging technology for the investigation of various cancers. His previous work has encompassed breast cancer, prostate cancer, and glioblastoma, an aggressive and common form of brain tumour. Glioblastoma, much like ovarian cancer, exhibits diverse subtypes with differing metabolic profiles, which can be effectively imaged to predict treatment responses. The initial clinical study in Cambridge employing this technique, published in 2020, focused on breast cancer patients.
The Urgent Need for Advanced Ovarian Cancer Diagnostics
The statistics surrounding ovarian cancer underscore the critical need for such diagnostic advancements. In the UK alone, approximately 7,500 women are diagnosed with ovarian cancer annually. A sobering majority, around 5,000 of these diagnoses, pertain to the most aggressive subtype, high-grade serous ovarian cancer (HGSOC).
The cure rates for all forms of ovarian cancer remain dismally low. In England, only 43% of women survive for five years beyond their diagnosis. A significant contributing factor to this poor prognosis is the often-subtle nature of ovarian cancer symptoms, which can lead to delayed diagnosis. By the time a diagnosis is made, the disease has frequently spread, complicating both imaging and treatment strategies. This makes the development of non-invasive, highly sensitive imaging techniques that can provide rapid, actionable information even more paramount.
Broader Clinical Applications and Future Outlook
The success of hyperpolarized carbon-13 imaging in predicting treatment response in ovarian cancer cell models opens avenues for its application in other malignancies. Professor Brindle’s ongoing research has already demonstrated its utility in breast cancer and glioblastoma, both of which exhibit intratumoural heterogeneity that influences treatment outcomes. The ability to non-invasively assess this heterogeneity across multiple tumour sites, as is common in advanced ovarian cancer, represents a paradigm shift in personalized oncology.
The implications of this research extend beyond mere prediction. By enabling oncologists to identify non-responding tumours early, it facilitates a quicker transition to alternative treatment strategies, thereby avoiding prolonged exposure to ineffective therapies and their associated toxicities. This not only improves the chances of successful treatment but also enhances the quality of life for patients undergoing arduous cancer therapies.
The rigorous scientific validation presented in Oncogene is a testament to the collaborative efforts of researchers at the University of Cambridge and its affiliated institutes. As the technique moves towards clinical trials, the hope is that it will soon be integrated into standard clinical practice, offering a beacon of hope for ovarian cancer patients and their families by providing more precise, timely, and ultimately, more effective cancer care. The journey from laboratory discovery to patient bedside is often a long one, but the potential impact of this hyperpolarized MRI technique on the lives of countless individuals battling ovarian cancer makes this a critical and highly anticipated development.
